These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38593352)

  • 1. Molnupiravir: Mechanism of action, clinical, and translational science.
    Maas BM; Strizki J; Miller RR; Kumar S; Brown M; Johnson MG; Cheng M; De Anda C; Rizk ML; Stone JA
    Clin Transl Sci; 2024 Feb; 17(2):e13732. PubMed ID: 38593352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template.
    Gordon CJ; Tchesnokov EP; Schinazi RF; Götte M
    J Biol Chem; 2021 Jul; 297(1):100770. PubMed ID: 33989635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis.
    Kabinger F; Stiller C; Schmitzová J; Dienemann C; Kokic G; Hillen HS; Höbartner C; Cramer P
    Nat Struct Mol Biol; 2021 Sep; 28(9):740-746. PubMed ID: 34381216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of pharmacokinetics, safety, and tolerability following twice-daily administration of molnupiravir for 10 days in healthy participants.
    Iwamoto M; Duncan KE; Wickremasingha PK; Zhao T; Liberti MV; Lemoine L; Decaesteker T; Rottey S; Maas BM; Gillespie G; Stoch SA
    Clin Transl Sci; 2023 Oct; 16(10):1947-1956. PubMed ID: 37526305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molnupiravir; molecular and functional descriptors of mitochondrial safety.
    Wallace KB; Bjork JA
    Toxicol Appl Pharmacol; 2022 May; 442():116003. PubMed ID: 35358570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decoding molnupiravir-induced mutagenesis in SARS-CoV-2.
    Menéndez-Arias L
    J Biol Chem; 2021 Jul; 297(1):100867. PubMed ID: 34118236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I, randomized, placebo-controlled study of molnupiravir in healthy Japanese to support special approval in Japan to treat COVID-19.
    Nakamura K; Fujimoto K; Hasegawa C; Aoki I; Yoshitsugu H; Ugai H; Yatsuzuka N; Tanaka Y; Furihata K; Maas BM; Wickremasingha PK; Duncan KE; Iwamoto M; Stoch SA; Uemura N
    Clin Transl Sci; 2022 Nov; 15(11):2697-2708. PubMed ID: 36053806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molnupiravir for the treatment of COVID-19.
    Santani BG; LeBlanc BW; Thakare RP
    Drugs Today (Barc); 2022 Jul; 58(7):335-350. PubMed ID: 35851869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.
    Jayk Bernal A; Gomes da Silva MM; Musungaie DB; Kovalchuk E; Gonzalez A; Delos Reyes V; Martín-Quirós A; Caraco Y; Williams-Diaz A; Brown ML; Du J; Pedley A; Assaid C; Strizki J; Grobler JA; Shamsuddin HH; Tipping R; Wan H; Paschke A; Butterton JR; Johnson MG; De Anda C;
    N Engl J Med; 2022 Feb; 386(6):509-520. PubMed ID: 34914868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity.
    Yip AJW; Low ZY; Chow VTK; Lal SK
    Viruses; 2022 Jun; 14(6):. PubMed ID: 35746815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molnupiravir: an antiviral drug against COVID-19.
    Dave B; Shah KC; Chorawala MR; Shah N; Patel P; Patel S; Shah P
    Arch Virol; 2023 Sep; 168(10):252. PubMed ID: 37710056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molnupiravir maintains antiviral activity against SARS-CoV-2 variants and exhibits a high barrier to the development of resistance.
    Strizki JM; Gaspar JM; Howe JA; Hutchins B; Mohri H; Nair MS; Kinek KC; McKenna P; Goh SL; Murgolo N
    Antimicrob Agents Chemother; 2024 Jan; 68(1):e0095323. PubMed ID: 38047645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive genotoxicity and carcinogenicity assessment of molnupiravir.
    Escobar PA; Sobol Z; Miller RR; Ferry-Martin S; Stermer A; Jacob B; Muniappa N; Sanchez RI; Blanchard KT; Galijatovic-Idrizbegovic A; Amin RP; Troth SP
    Toxicol Sci; 2024 Dec; 202(2):278-290. PubMed ID: 39302733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molnupiravir and Its Antiviral Activity Against COVID-19.
    Tian L; Pang Z; Li M; Lou F; An X; Zhu S; Song L; Tong Y; Fan H; Fan J
    Front Immunol; 2022; 13():855496. PubMed ID: 35444647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New conjugates based on N4-hydroxycytidine with more potent antiviral efficacy in vitro than EIDD-2801 against SARS-CoV-2 and other human coronaviruses.
    Siniavin AE; Gushchin VA; Shastina NS; Darnotuk ES; Luyksaar SI; Russu LI; Inshakova AM; Shidlovskaya EV; Vasina DV; Kuznetsova NA; Savina DM; Zorkov ID; Dolzhikova IV; Sheremet AB; Logunov DY; Zigangirova NA; Gintsburg AL
    Antiviral Res; 2024 May; 225():105871. PubMed ID: 38555022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. β-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells.
    Zhou S; Hill CS; Sarkar S; Tse LV; Woodburn BMD; Schinazi RF; Sheahan TP; Baric RS; Heise MT; Swanstrom R
    J Infect Dis; 2021 Aug; 224(3):415-419. PubMed ID: 33961695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. β-d-N
    Konishi K; Kusakabe S; Kawaguchi N; Shishido T; Ito N; Harada M; Inoue S; Maeda K; Hall WW; Orba Y; Sawa H; Sasaki M; Sato A
    Antiviral Res; 2024 Sep; 229():105977. PubMed ID: 39089332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized Adults.
    Caraco Y; Crofoot GE; Moncada PA; Galustyan AN; Musungaie DB; Payne B; Kovalchuk E; Gonzalez A; Brown ML; Williams-Diaz A; Gao W; Strizki JM; Grobler J; Du J; Assaid CA; Paschke A; Butterton JR; Johnson MG; De Anda C
    NEJM Evid; 2022 Feb; 1(2):EVIDoa2100043. PubMed ID: 38319179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative docking and molecular dynamics studies of molnupiravir (EIDD-2801): implications for novel mechanisms of action on influenza and SARS-CoV-2 protein targets.
    Istifli ES; Okumus N; Sarikurkcu C; Kuhn ER; Netz PA; Tepe AS
    J Biomol Struct Dyn; 2024 Sep; 42(15):8202-8214. PubMed ID: 37811782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small-Molecule Antiviral β-d-
    Agostini ML; Pruijssers AJ; Chappell JD; Gribble J; Lu X; Andres EL; Bluemling GR; Lockwood MA; Sheahan TP; Sims AC; Natchus MG; Saindane M; Kolykhalov AA; Painter GR; Baric RS; Denison MR
    J Virol; 2019 Dec; 93(24):. PubMed ID: 31578288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.